You are here: Industry Insights > metastatic colorectal cancer

News List

Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA’s Fast Track Designation PharmaSources/Xiaoyaowan
July 06, 2020
Hutchison MediPharma’s targeted anticancer drug: fruquintinib has recently received the Fast Track designation granted by the FDA for the treatment of patients with metastatic colorectal cancer (mCRC).
VBL Enrolls First Patients in VB-111 Trial for Metastatic Colorectal Cancer americanpharmaceuticalreview
September 18, 2020
VBL Therapeutics announced the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer.
FDA Approves Encorafenib, Cetuximab Combination for Metastatic Colorectal Cancer americanpharmaceuticalreview
April 10, 2020
The U.S. Food and Drug Administration (FDA) approved encorafenib (BRAFTOVI, Array BioPharma) in combination with cetuximab for the treatment of adult patients ...
Continuing Full Induction Regimen Not Beneficial in Metastatic CRC drugs
December 23, 2019
For patients with metastatic colorectal cancer, continuing full cytotoxic chemotherapy until progression offers no benefit over observation ...
China approves first "Made in China" cancer drug biospectrumasia
September 07, 2018
The colorectal cancer drug developed by Chi-Med are to be marketed in China under the brand name Elunate
Cross-Industry Collaboration Announced to Treat Metastatic Colorectal Cancer americanpharmaceuticalreview
September 07, 2018
GNS Healthcare announced a cross-industry partnership with Amgen and the Alliance for Clinical Trials in Oncology (Alliance) that will apply causal artificial intelligence (AI) and simulation to combined clinical trial data to identify factors that drive
FDA approves Vectibix for use in wild-type RAS metastatic colorectal cancer cphi-online
July 04, 2017
First-and-only fully human monoclonal anti-epidermal growth factor receptor antibody approved by the FDA for this patient population.